Organigram Q2 FY2026: OGI Drops 15%, Germany Bet On

Organigram Global filed its fiscal second-quarter 2026 results on May 13, 2026, and the market did not love what it saw. The Canadian-headquartered licensed producer reported net revenue of CAD $59.8 million, down roughly 9% year over year, alongside adjusted EBITDA of just CAD $0.9 million — an 82% collapse from the prior-year quarter. The stock, which trades under the ticker OGI on the Nasdaq and TSX, fell about 15% on the print and touched a fresh 52-week low.

That is the kind of quarter that, on its own, would frame a cannabis company as struggling to find a footing. But the more interesting line in the release was not the revenue miss — it was the company's revised forward guidance and the new center of gravity for that guidance: the recently completed acquisition of Germany's Sanity Group.

Organigram's Q2 was a difficult quarter on the home market. It was also, simultaneously, the moment the company effectively repositioned itself as a Europe-and-Canada operator rather than a Canada-first one with international optionality. For investors trying to figure out whether OGI is a value name or a value trap in May 2026, the Sanity Group story is the thread to pull on.

What the Q2 FY2026 numbers actually said

The headline financials from Organigram's second-quarter fiscal 2026 results paint a clear picture of operational pressure across multiple product categories.

Net revenue: CAD $59.8 million, down approximately 9% year over year on both gross and net measures.

Adjusted EBITDA: CAD $0.9 million, down roughly 82% year over year. The line item that bulls had been pointing to as evidence of operational discipline collapsed in a single quarter.

Net result: A net loss of approximately CAD $0.9 million, swinging from prior profitability.

Stock reaction: OGI shares dropped about 15% on the print and hit a fresh 52-week low, capping a difficult stretch for the broader cannabis equity complex.

Management was specific about what went wrong. CEO commentary on the earnings call attributed the weakness to operational issues in two specific categories — vapes and infused pre-rolls — combined with softer Canadian recreational market growth and what the company described as "international flower spec challenges" for some export shipments. In other words: the products that have been driving the broader cannabis category's growth are also the products where Organigram had the most execution friction this quarter.

The vape weakness in particular is worth flagging because it mirrors what other Canadian licensed producers have seen in recent quarters. The Canadian vape category has been pressured by a combination of inventory adjustments at provincial wholesalers, shifts in product preferences (toward live resin and live rosin formats and away from distillate), and tighter margins as competition has intensified. Organigram is not alone in feeling that pressure, but the magnitude of the EBITDA hit suggests it absorbed more of the impact than peers in this particular three-month window.

The Sanity Group acquisition, explained

The reason Organigram's Q2 print did not produce a deeper sell-off is that the company also closed and folded in the Sanity Group acquisition, a transaction that materially changes what Organigram is as a business.

Sanity Group is a German cannabis company with a meaningful position in the country's medical cannabis market — the largest medical cannabis market in Europe and, depending on which quarter you measure, the fastest-growing major market in the world. Organigram acquired Sanity to give itself a built operating presence in Germany rather than continuing to serve the market through export-only arrangements.

In its Q2 release and on the earnings call, Organigram laid out specific expectations for what Sanity adds to the consolidated business:

Quarterly revenue contribution: Sanity is expected to generate an average of approximately EUR 25 million in quarterly revenue over the next year, scaling as the German medical market continues to expand and as Sanity's distribution footprint deepens.

European platform: The company described Sanity not just as a German operator but as a platform for expansion across Europe, with explicit mentions of Switzerland, the United Kingdom, Poland, and the Czech Republic as next-step markets.

Switzerland angle: The Swiss recreational pilot program is described as a smaller but potentially high-margin opportunity, and Sanity gives Organigram a credible operating partner to participate in that pilot rather than building from scratch.

Updated guidance: Reflecting the Sanity contribution, Organigram raised fiscal 2026 net revenue guidance to above CAD $350 million, with adjusted EBITDA and adjusted gross margin expected to exceed fiscal 2025 levels. That is a meaningful bump in the topline guide and the kind of forward-looking number that investors typically need to see when current-quarter results disappoint.

The strategic logic is straightforward. Canada is a mature, oversupplied recreational market with thin margins and consolidating retail. Germany is a younger, faster-growing medical market with more room for premium positioning and pricing power. Tilting the revenue mix toward Germany is one of the few ways a Canadian LP can structurally improve the quality of its earnings.

Why Germany is the entire bull case in 2026

Germany legalized recreational adult use in 2024 and operates an unusually structured market — limited commercial recreational sales, but a robust and rapidly expanding medical cannabis system that doctors can prescribe with relative ease. The result has been an explosion in patient numbers and import volumes that has caught most observers off guard.

Recent industry data has Germany's medical cannabis patient population approaching the high hundreds of thousands and rising every quarter. Imports of medical cannabis flower have hit record levels, with Canadian licensed producers — including Organigram, Tilray, and High Tide's Remexian subsidiary — competing aggressively for supply contracts and pharmacy distribution.

In that landscape, owning a domestic German operator is qualitatively different from exporting to one. A domestic operator can build pharmacy relationships directly, manage product registrations more efficiently, and respond to demand swings without the lead time of an international shipment. The Sanity Group acquisition gives Organigram that kind of in-country presence.

The risks are real. German cannabis policy is still evolving, and any meaningful regulatory tightening — particularly around prescription guidelines or pharmacy distribution — could compress the market faster than expected. Pricing competition among Canadian, German, and other European supply sources could erode the margin advantage that has made Germany attractive in the first place. And the EUR 25 million quarterly revenue figure is a forward expectation, not a banked outcome; Sanity has to actually deliver that level of consistent demand for the math to work.

But the alternative — relying on a flat-to-declining Canadian recreational market for the bulk of revenue — is not a recipe for re-rating the stock either. Management is clearly making the bet that international growth, particularly in Germany, has to do the heavy lifting for the next several quarters.

Where this leaves OGI investors

For investors holding OGI through the May 13 print, Q2 FY2026 was the kind of quarter that tests conviction. The Canadian operating business is under real pressure, and the EBITDA collapse is not something that gets explained away in a single conference call. The company's longer-term thesis now rests, almost explicitly, on Germany executing.

Three things to watch over the next two quarters:

Sanity's actual revenue contribution. The first full quarter of Sanity inside the Organigram consolidated results will tell investors how seriously to take the EUR 25 million quarterly run-rate. A meaningful overshoot or undershoot in that number will move the stock more than the legacy Canadian segment.

Canadian segment stabilization. Organigram does not need the Canadian business to grow rapidly — but it needs it to stop deteriorating. Vape category recovery, infused pre-roll execution, and improved provincial wholesale dynamics are the specific levers to watch.

Broader cannabis sector tone. The May 13 OGI sell-off came amid a generally weak day for cannabis stocks; 23 of 38 tracked tickers finished below the prior close. Sector beta is real, and a more constructive tape would give Organigram more room to absorb a soft quarter.

Cannabis investors have lived through enough "international expansion" stories that promised more than they delivered to be appropriately skeptical of any new one. Sanity is a real operating asset in a real and growing market, but the burden is now on Organigram to translate that into reported financials over the next several quarters. Retail investors comparing Organigram against the rest of the cannabis equity complex can also browse Budpedia's directory of verified cannabis dispensaries to see which operators are actually shipping product where.

Key Takeaways

• Organigram reported Q2 FY2026 net revenue of CAD $59.8 million, down 9% year over year, with adjusted EBITDA of CAD $0.9 million — an 82% drop.
• OGI stock fell about 15% on the May 13, 2026 earnings print and touched a fresh 52-week low.
• Management blamed weakness on vapes, infused pre-rolls, softer Canadian growth, and international flower spec challenges.
• The recently completed Sanity Group acquisition is expected to contribute about EUR 25 million in quarterly revenue and serve as a platform for Switzerland, the U.K., Poland, and the Czech Republic.
• Updated FY2026 guidance now calls for net revenue above CAD $350 million, with adjusted EBITDA and gross margin above fiscal 2025 levels — a forecast that depends almost entirely on Germany executing.

Explore cannabis news, find dispensaries, and join the community at Budpedia.